Mechanisms of Immune Evasion and Novel Treatments for Relapsed and Refractory Diffuse Large B-cell Lymphoma
Oncology Advances · 2024
DOI: 10.14218/ona.2024.00006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Advances, 2024. Verfasst von Kamen W. Kossow und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive B-cell non-Hodgkin lymphoma. While a substantial fraction of patients are cured with frontline chemoimmunotherapy, approximately 30% of cases subsequently relapse. DLBCL immune evasion and refractory disease can occur via several mechanisms: downregulation or loss of major histocompatibility complex expression, immune checkpoint activation, tumor microenvironment modulation, and resistance to apoptosis. Addressing these mechanisms of immune evasion in DLBCL has been a focus of ongoing research, leading to the exploration of new therapies. Here, we review the mechanisms of immune evasion and novel immunotherapy treatment strategies for DLBCL.
Zitieren
APA
Kossow, K. W., Bennett, J. G., & Hoffmann, M. S. (2024). Mechanisms of Immune Evasion and Novel Treatments for Relapsed and Refractory Diffuse Large B-cell Lymphoma. Oncology Advances. https://doi.org/10.14218/ona.2024.00006
Vancouver
Kossow KW, Bennett JG, Hoffmann MS. Mechanisms of Immune Evasion and Novel Treatments for Relapsed and Refractory Diffuse Large B-cell Lymphoma. Oncology Advances. 2024. doi:10.14218/ona.2024.00006
BibTeX
@article{Kossow2024,
author = {Kossow, Kamen W. and Bennett, Joseph G. and Hoffmann, Marc S.},
title = {Mechanisms of Immune Evasion and Novel Treatments for Relapsed and Refractory Diffuse Large B-cell Lymphoma},
journal = {Oncology Advances},
year = {2024},
doi = {10.14218/ona.2024.00006}
}
EUVIMED